tiprankstipranks
Advertisement
Advertisement
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
PremiumRatingsDenali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
1M ago
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
Premium
The Fly
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
1M ago
Craig-Hallum bullish on  Spruce Biosciences, initiates with a Buy
Premium
The Fly
Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
2M ago
Denali Regains DNL593 Rights After Takeda Collaboration Ends
PremiumCompany AnnouncementsDenali Regains DNL593 Rights After Takeda Collaboration Ends
2M ago
Denali Therapeutics Secures $200 Million Royalty Funding
Premium
Company Announcements
Denali Therapeutics Secures $200 Million Royalty Funding
3M ago
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100